

Restoring patient function and vitality

Regenerative medicine is an innovative and expanding field, investigating the potential of tissue engineering and molecular biology to offer a natural recovery by triggering a response through the body's own cells

With the demand for less invasive and longer-lasting treatments, Tissue Regenix Group is setting the benchmark for the industry with its novel regenerative platform technologies. dCELL Technology, for the treatment of soft tissues, and BioRinse Technology, offering a regenerative solution for the treatment of bone defects caused by trauma or disease.

BIORINSE, ASSURED OSTEOINDUCTIVITY

Products treated with the BioRinse process are independently verified post manufacture to ensure they contain the essential bone growth factors prior to release

This distinction means that BioRinse products are unique in the sense that they're the only products on the market which go through in-vivo and in-vitro testing post manufacture to be verified to induce bone regeneration.

Using unrivalled cellular science, Tissue Regenix has been able to develop products at the cutting-edge of healthcare innovations exhibiting class-leading handling characteristics and patient outcomes.

This falls directly in line with growing patient demand. As the population gets older, more and more people are looking to stay active for longer. A return to an active, healthy lifestyle can be assisted through the use of BioRinse regenerative products.

For example, defects replaced by a non-osteoinductive product reduce the potential for rapid bone regeneration. The use of an osteoinductive BioRinse product would assist the

potential for natural tissue regeneration, ensuring freedom of movement and healthy bone structure.

With practical applications in spinal surgery, orthopaedics and dentistry, the uses for the BioRinse portfolio are vast. The process transforms donated human bone into various mouldable forms while preserving the natural growth factors needed to regenerate healthy bones post-implantation, making it highly desirable for both patients and clinicians alike.

With increasing financial pressures on the healthcare system due to a growing and ageing population; there's a focus on the development of novel regenerative treatments. The innovative solutions developed by Tissue Regenix are at the forefront of these developments with their novel technology platforms helping to alleviate this strain by providing practical solutions for patients.

With all Tissue Regenix products, patient safety is paramount. The verified osteoinductivity maximises the regeneration of native bone. Unlike existing solutions, the BioRinse products contain no artificial carriers which can limit the bone regeneration achieved. Produced in different physical forms, BioRinse products offer clinicians a treatment choice tailored to the patient's needs; and being stored at an ambient temperature with a five-year shelf life means there are no additional logistical requirements.

Tissue Regenix's flagship product ConCelltrate 100, along with other BioRinse products, is now available in the UK.

Tissue Regenix Group was spun out of the University of Leeds in 2006 to commercialise dCELL Technology, a novel decellularization technique for soft tissue. The first product, DermaPure, a decellularised human dermis, was launched in the USA in 2014 and has since seen growing traction in wound care and surgical settings. OrthoPure XT, a decellularised porcine tendon, will be the first of the dCELL products to launch in the EU in 2019.


In 2017, Tissue Regenix acquired CellRight Technologies and with it a complementary process for the decellularization of bone, BioRinse. With applications areas in biosurgery, orthopaedics, spine and dental, the company has seen growing clinical success in the US and has recently entered the European markets.



tissuregenix.com
T: 0330 430 3052

Tissue Regenix Group
Unit 1 & 2, Astley Lane
Industrial Estate,
Astley Way, Swillington,
Leeds LS26 8XT

Bioactive Regenerative Solutions



**VERIFIED
OSTEOINDUCTIVITY,
EVERY LOT,
EVERY TIME**